Longevity Startup Begins First Human Trial of ER-100 Technology for Age-Related Sight Loss
A longevity startup has dosed its first human patient with ER-100 technology, an experimental approach designed to reverse age-related sight loss. The company claims this technology can reverse aging in cells, and this trial marks the first time it has been tested in a human subject.
The therapy targets degenerative eye conditions that commonly develop with aging, potentially offering a novel approach to treating vision decline. If successful, the treatment could represent a significant advancement in addressing age-related visual impairment through cellular rejuvenation.